UNSPSC 51314374: Menthol/pheniramine/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.

UNSPSC 51314374 Menthol/pheniramine/phenylephrine is a Commodity-tier code that in recent state and local procurement activity covers a broader range of pharmaceuticals and over-the-counter health products than its narrow code name suggests. Recent opportunities under this classification include naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products supplied through authorized wholesalers, and direct-to-manufacturer prescription fulfillment programs. State health and human services agencies, county health departments, and cooperative purchasing alliances (including multistate vehicles) are the primary issuing bodies. The work involves product specification, pricing negotiation, compliance with Good Manufacturing Practices and Drug Supply Chain Security Act requirements, and logistics coordination across multiple delivery points or wholesaler networks.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, requiring electronic bid submission with all shipping included. The Texas Health and Human Services Commission released an RFI on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at establishing direct contracts between the state pharmacy benefit program and manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026 (responses due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to state and local facilities across participating jurisdictions including Oregon, requiring vendor compliance with cGMP and DSCSA standards, relationships with authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., and a 3 percent administrative fee on all purchases.